Home / Products / Antibiotics / CEFAERO-500
Click image to inspect pack details
Antibiotics Marketed by Aerochem Neutron

CEFAERO-500

Formulation Code AC-476
Commercial Status Active Product Information Available

Product Overview & Formulation Profile

Description

Cefuroxime Axetil Tablets 500 mg

CEFAERO-500 contains cefuroxime axetil, an oral second-generation cephalosporin antibiotic that is converted to active cefuroxime after administration.

Cefuroxime interferes with bacterial cell-wall synthesis, producing bactericidal activity against susceptible organisms. Its antibacterial spectrum includes selected Gram-positive and Gram-negative bacteria.

The 500 mg strength is used in certain established cefuroxime treatment regimens, including selected bacterial respiratory tract and skin infections. It is not automatically preferable to the 250 mg strength; the appropriate dose depends on the approved indication and individual clinical requirements.

Treatment should consider antimicrobial susceptibility, renal function and applicable prescribing recommendations.

Dosage Form: Tablets
Strength: 500 mg
Packing:  10 x 10 Alu Alu

Prescription medicine. Use under the supervision of a registered medical practitioner.

Composition & Formulation Details

Features

  • Oral cephalosporin antibiotic: Contains cefuroxime axetil, a second-generation cephalosporin.

  • Bactericidal action: Inhibits bacterial cell-wall synthesis.

  • Antibacterial activity: Active against selected susceptible Gram-positive and Gram-negative organisms.

  • 500 mg tablet strength: Used in specific cefuroxime dosing regimens where clinically indicated.

  • Treatment considerations: Appropriate use depends on infection type, bacterial susceptibility, renal function and patient assessment.

Conditions

Therapeutic Indications — 


Acute Bacterial Exacerbation of Chronic Bronchitis: Treatment of selected infections caused by susceptible bacterial pathogens.

  • Uncomplicated Skin and Skin-Structure Infections: Treatment of infections caused by susceptible bacteria.

  • Early Lyme Disease: An indication included in certain international cefuroxime axetil 500 mg prescribing information

The 500 mg strength should not be presented as universally superior to 250 mg or as appropriate for every infection treated with cefuroxime.


Professional Product Enquiries

Verified product information, formulation specifications, and commercial supply pathways for registered healthcare professionals, institutions, and trade partners.

Product Information

Review verified active composition, strength, dosage form, and packaging details on this page.

View Specifications

Healthcare Professional Enquiry

Request formulation literature, technical specifications, or product communication from our commercial team.

Submit Product Enquiry

Commercial Supply Enquiry

Connect regarding institutional supply requirements, trade distribution, or third-party contract manufacturing.

Commercial Enquiry

Professional Product Information

This product information is intended for registered healthcare professionals, medical practitioners, and authorized distribution partners. Product manufacturing is coordinated through eligible facility partners under applicable licences.

Product Enquiry

Request Formulation Details

Request information about CEFAERO-500 for professional use.

Please enter the numeric sum to verify you are a human visitor.
Therapeutic Alternatives

Related Formulations

SULTAVIN Formulation
AEROCLAV -625 Formulation
AEROFLOX 200 Formulation
A.G 250 Formulation
Product Information

Need specifications for this formulation?

Request verified product information for professional use, or send a separate business enquiry for manufacturing or partnership discussions.

WhatsApp: +91 9512047000